Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03371849 Completed - Healthy Clinical Trials

PK and Safety Study of HCP1102, HGP0813 and HGP1408

Start date: July 19, 2017
Phase: Phase 1
Study type: Interventional

This study is a randomized, open label, single dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety/tolerability of HCP1102 in comparison to HGP0813 and HGP1408 administered in healthy male volunteers.

NCT ID: NCT03363477 Completed - Healthy Clinical Trials

Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers

Start date: September 25, 2015
Phase: Phase 1
Study type: Interventional

To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers. As secondary objective, to evaluate the safety and tolerability of enoxaparin Rovi (100 mg/mL) in healthy volunteers.

NCT ID: NCT03353636 Completed - Healthy Clinical Trials

Bioavailability of Magnesium Supplements

Start date: June 27, 2016
Phase: N/A
Study type: Interventional

The primary objective of this clinical trial is to demonstrate the superiority of Natural Calm magnesium powder with respect to absorption when compared to three marketed forms of magnesium (two magnesium bisglycinate powders and magnesium citrate capsules). The primary endpoints were serum magnesium AUC (0-8h) and urine magnesium AUC (0-8h) after a single dose of 150 mg elemental magnesium.

NCT ID: NCT03350386 Completed - Healthy Clinical Trials

Drug-drug Interaction Study of FYU-981 and Oxaprozin

Start date: November 2, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers.

NCT ID: NCT03350373 Completed - Healthy Clinical Trials

Clinical Pharmacology of FYU-981 (Final Formulation)

Start date: November 6, 2017
Phase: Phase 1
Study type: Interventional

This is a randomized, open-label, 2-period crossover study. The purpose of this study is to assess the pharmacokinetics and safety after single oral administration of final formulation of FYU-981 to healthy male adults in fasted and fed conditions. Participants are randomized to fasted (n=6) or fed conditions (n=6) in each step. The effect of food to pharmacokinetics of FYU-981 is also investigated.

NCT ID: NCT03349697 Completed - Healthy Clinical Trials

Phyllantus Amarus for the Protection of Liver Health

Start date: July 13, 2010
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, placebo controlled crossover study. The purpose of this study is to assess the ability of Phyllantus amarus to protect the liver against temporary stress including oxidative stress induced by alcohol consumption.

NCT ID: NCT03340870 Completed - Healthy Clinical Trials

A Study to Evaluate Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy Volunteers

Start date: October 20, 2014
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the Pharmacokinetics (PK) data of perfluorobutane (PFB) in blood and exhaled air following intravenous (I.V.) bolus injection of Sonazoid™ in healthy volunteers.

NCT ID: NCT03335085 Completed - Healthy Clinical Trials

Oxytocin Administration and Emotion Recognition Abilities in Adults Reporting Adverse Childhood Experiences

Start date: July 1, 2011
Phase: N/A
Study type: Interventional

This study evaluates whether intranasal administration of a single dose of oxytocin improves the ability to recognize emotional states. In a cross-over design, half of the participants first received oxytocin, the other half first received placebo.

NCT ID: NCT03333369 Completed - Healthy Clinical Trials

Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission

Start date: May 15, 2014
Phase: Early Phase 1
Study type: Interventional

The dopamine hypothesis of schizophrenia implies that alterations in the dopamine system cause functional abnormalities in the brain that may converge to aberrant salience attribution and eventually lead to psychosis. Indeed, widespread brain disconnectivity across the psychotic spectrum has been revealed by resting-state functional magnetic resonance imaging (rs-fMRI). However, the dopaminergic involvement in intrinsic functional connectivity (iFC) and its putative relationship to the development of psychotic spectrum disorders remains partly unclear - in particular at the low-end of the psychosis continuum. Therefore, the investigators examined dopamine-induced changes in striatal iFC and their modulation by psychometrically assessed schizotypy. The randomized, double-blind placebo-controlled study design included 54 healthy, right-handed male participants. Each participant was assessed with the Schizotypal Personality Questionnaire (SPQ) and underwent 10 min of rs-fMRI scanning. Participants then received either a placebo or 200 mg of L-DOPA, a dopamine precursor. The investigators analyzed iFC of six striatal seeds that are known to evoke modulation of dopamine-related networks. The investigators hypothesized that, within the L-DOPA treatment group, the striatal iFC would be disrupted due to increased availability of dopamine. The investigators further hypothesized that individuals with high schizotypal scores would show a disruption of striatal connectivity, as has been reported with schizophrenia. In addition, the investigators hypothesized that the L-DOPA-dependent change in striatal iFC would interact with the severity of positive symptoms, as has been found in previous studies in non-clinical psychosis. The investigators anticipated this symptom-dependent change, especially in the ventral striatal regions, because these are thought to modulate cortico-striatal loops associated with cognition and emotion.

NCT ID: NCT03325686 Completed - Healthy Clinical Trials

Vitamin D Supplementation in Physical Performance

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

This study was performed to evaluate the efficacy of weekly vitamin D supplementation on athletic performance in Iranian athletes